Single-dose study for healthy adults and early Alzheimer's participants
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 35 kg/m2 on the BMI scale
- For healthy volunteer parts: you must be in good health without significant medical conditions
- For the Alzheimer's part: you must have mild cognitive impairment or mild Alzheimer's dementia
- For the Alzheimer's part: you must have a Mini-Mental State Exam (MMSE) score between 20 and 28
- For the Alzheimer's part: you must have a positive blood test for pTau217, a protein linked to Alzheimer's
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.